- Home
- ARQT vs CNTA Comparison
ARQT vs CNTA Comparison
Compare ARQT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- CNTA
- Stock Information
- Founded
- ARQT 2016
- CNTA 2020
- Country
- ARQT United States
- CNTA United Kingdom
- Employees
- ARQT N/A
- CNTA N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- CNTA Health Care
- Exchange
- ARQT Nasdaq
- CNTA Nasdaq
- Market Cap
- ARQT 1.7B
- CNTA 1.9B
- IPO Year
- ARQT 2020
- CNTA 2021
- Fundamental
- Price
- ARQT $14.29
- CNTA $16.81
- Analyst Decision
- ARQT Strong Buy
- CNTA Strong Buy
- Analyst Count
- ARQT 7
- CNTA 11
- Target Price
- ARQT $18.67
- CNTA $28.90
- AVG Volume (30 Days)
- ARQT 1.5M
- CNTA 1.1M
- Earning Date
- ARQT 08-06-2025
- CNTA 08-12-2025
- Dividend Yield
- ARQT N/A
- CNTA N/A
- EPS Growth
- ARQT N/A
- CNTA N/A
- EPS
- ARQT N/A
- CNTA N/A
- Revenue
- ARQT $212,819,000.00
- CNTA $15,000,000.00
- Revenue This Year
- ARQT $61.83
- CNTA N/A
- Revenue Next Year
- ARQT $36.55
- CNTA N/A
- P/E Ratio
- ARQT N/A
- CNTA N/A
- Revenue Growth
- ARQT 100.03
- CNTA 118.88
- 52 Week Low
- ARQT $7.86
- CNTA $9.10
- 52 Week High
- ARQT $17.75
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- ARQT 46.02
- CNTA 67.45
- Support Level
- ARQT $14.44
- CNTA $15.05
- Resistance Level
- ARQT $15.38
- CNTA $17.69
- Average True Range (ATR)
- ARQT 0.66
- CNTA 0.77
- MACD
- ARQT -0.09
- CNTA 0.08
- Stochastic Oscillator
- ARQT 10.19
- CNTA 70.10
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.